What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “LM-302 intravenous-injection every 2 weeks on Day 1 of each 14-day cycle”In the company’s words, NCT06351020 on ClinicalTrials.gov
- Tested for
- Locally Advanced or Metastatic GC and GCJ Adenocarcinoma, Malignant Neoplasms of Digestive Organs
- Main trialPhase 3
- “This study will assess the efficacy and safety of LM-302 Versus Treatment of Physician's Choice (TPC) in Subjects With locally advanced or metastatic, Claudin (CLDN) 18.2-positive, Gastric or Gastroesophageal Junction Adenocarcinoma who have progressed on or after 2 lines of systemic therapy”In the company’s words, NCT06351020 on ClinicalTrials.gov
Coming up1
- 6 Aug 2031Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 10 Nov 2026 | LM-302 for the Treatment of Subjects With Claudin18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma. | |
| Phase 2Recruiting | 6 Aug 2031 | A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study | |
| Phase 1/2Completed | 14 Nov 2023 | Study of LaNova Medicines(LM)-302 in Combination With Toripalimab in Patients With Advanced Solid Tumors | |
| Phase 1/2Completed | 10 Jan 2025 | Study of LM-302 in Patients With Advance Solid Tumors |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026